- Home
- WPP vs AXSM Comparison
WPP vs AXSM Comparison
Compare WPP & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPP
- AXSM
- Stock Information
- Founded
- WPP 1985
- AXSM 2012
- Country
- WPP United Kingdom
- AXSM United States
- Employees
- WPP N/A
- AXSM N/A
- Industry
- WPP Advertising
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- WPP Consumer Discretionary
- AXSM Health Care
- Exchange
- WPP Nasdaq
- AXSM Nasdaq
- Market Cap
- WPP 5.5B
- AXSM 5.1B
- IPO Year
- WPP N/A
- AXSM 2015
- Fundamental
- Price
- WPP $27.09
- AXSM $118.51
- Analyst Decision
- WPP Sell
- AXSM Strong Buy
- Analyst Count
- WPP 1
- AXSM 16
- Target Price
- WPP N/A
- AXSM $176.56
- AVG Volume (30 Days)
- WPP 500.2K
- AXSM 605.1K
- Earning Date
- WPP 08-07-2025
- AXSM 08-04-2025
- Dividend Yield
- WPP 9.63%
- AXSM N/A
- EPS Growth
- WPP 86.47
- AXSM N/A
- EPS
- WPP 0.47
- AXSM N/A
- Revenue
- WPP $19,423,208,660.00
- AXSM $495,033,000.00
- Revenue This Year
- WPP N/A
- AXSM $61.62
- Revenue Next Year
- WPP $3.26
- AXSM $59.02
- P/E Ratio
- WPP $11.22
- AXSM N/A
- Revenue Growth
- WPP N/A
- AXSM 69.83
- 52 Week Low
- WPP $24.28
- AXSM $75.56
- 52 Week High
- WPP $57.37
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- WPP 47.75
- AXSM 72.31
- Support Level
- WPP $26.27
- AXSM $102.67
- Resistance Level
- WPP $26.63
- AXSM $112.47
- Average True Range (ATR)
- WPP 0.45
- AXSM 3.25
- MACD
- WPP 0.43
- AXSM 1.55
- Stochastic Oscillator
- WPP 95.25
- AXSM 89.74
About WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.